Arsenic trioxide compound modulates multiple myeloma phenotypes: Assessment on cell line models

Iranian Journal of Public Health

Volumn 35, Issue 1, 2006, Pages 17-24

  Khorramizadeh, M R ^a   Saadat, F ^a   Allahyary, H ^a   Pezeshki, M ^a   Sarrafnejad, A ^a   Mirshafiey, A ^a   Safavifar, F ^b   Alimoghaddam, K ^b   Ghavamzadeh, A ^b   Sadeghian, S ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiogenesis; Apoptosis; Arsenic trioxide; Cytotoxicity; Karpas 707; MMP 2; Multiple myeloma

Indexed keywords

ARSENIC TRIOXIDE; GELATINASE A;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL DEATH; CELL PROLIFERATION; COLORIMETRY; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NICK END LABELING; PHENOTYPE; STATISTICAL SIGNIFICANCE; TUMOR VASCULARIZATION; ZYMOGRAPHY;

EID: 33645119094     PISSN: 22516085     EISSN: 22516093     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rojewski MT, Korper S, Schrezenmeier H (2004). Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma, 45: 2387-401.
2. Antman Karen H (2001). Introduction: The history of arsenic trioxide in cancer Therapy. The Oncologist, 6: 1-2.
3. Novick SC, Warrell RP Jr (2000). Arsenicals in hematologic cancers. Semin Oncol, 27: 495-501.
4. Hussein MA (2003). Trials of arsenic trioxide in multiple myeloma. Cancer Control, 10: 370-74.
5. Hussein MA (2001). Arsenic trioxide, a new immunomodulatory agent in the management of multiple myeloma. Medical Oncology, 18: 239-42.
6. Mohamad A Hussein (2002). Nontraditional cytotoxic therapies for relapsed/ refractory multiple myeloma. Oncologist, 7 Suppl 1:20-9.
7. Hallek M, Bergsagel PL, Anderson KC (1998). Multiple myeloma: increasing evidence for a multistep transformation process. Blood, 91: 3-21.
8. Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr (1999). Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol, 44: 417-21.
9. Shim MJ, Kim HJ, Yang SJ, Lee IS, Choi HI, Kim T (2002). Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. J Biochem Mol Biol, 35: 377-83.
10. Evens AM, Tallman MS, Gartenhaus RB (2004). The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res, 28: 891-900.
11. Kelly T, Borset M, Abe E, Gaddy-Kurten D, Sanderson RD (2000). Matrix metalloproteinases in multiple myeloma. Leuk Lymphoma, 37: 273-81.
12. Saadat F, Zomorodian K, Pezeshki M. Rezaie S, Khorramizadeh MR (2004). Inhibitory effect of Aspergillus fumigatus extract on matrix metalloproteinases expression. Mycopathologia, 158:33-37.
13. Druker BJ, O'Brien SG, Cortes J, Radich J (2002). Chronic myelogenous leukemia. Hematology, 1: 111-35.
14. Stephens DJLJ (1936). Therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia. Ann Intern Med, 9:1488.
15. Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, et al. (1999). Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute pro- myelocytic leukemia patients. Blood, 94: 3315-24.
16. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, et al. (1996). In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with down-regulation of Bcl-2 expression and modulation of PML-RARa/ PML proteins. Blood, 88: 1052-61.
17. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP (1999). Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Research, 59:1041-48.
18. Kim J, Yu W, Kovalski K, and Ossowski (1998). Requirement for specific protease in cancer cell intravasion as revealed by a novel semiquantitative PCR-based assay. Cell, 94:353-62.
19. Quigley JP, Armstrong PB (1998). Tumor cell intravasion Elucidated: The chick embryo opens the window. Cell, 94: 281-84.
20. Barille S, Akhoundi C, Collette M, Mellerin MP, Rapp MJ, Harousseau JL, Bataille R, Amiot M (1997). Amiot. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of pro MMP-2, and induction of MMP-1 by myeloma cells. Blood, 90: 1649-55.
21. Kaushal GP, Xiong X, Athota AB, Rozypal TL, Sanderson RD, Kelly T (1999). Syndycan-1 expression suppresses. the level of myeloma matrix metalloproteinase-9. Br J Haematol, 104: 365-73.
22. Roboz GJ, Dias S, Lain G, Lane WJ, Soignet SL, Warrell RP Jr, Rafii S (2000). Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood, 96: 1525-30.